Liquid Biopsy in CancerLiquid biopsies of blood, urine, or other body fluid such as ascites are gaining interest in cancer diagnostics and treatment. In this session Professor Helen Rizos will discuss liquid biopsies in melanoma – how they can monitor response, predict patient outcomes and current limitations in the application of liquid biopsies and Dr … Read more
Familial Cancer Syndromes and their Clinical ManagementThis webinar draws together interdisciplinary experts to focus on “Familial Cancer Syndromes and Clinical Management”, specifically to increase our understanding of inherited cancer risks and their clinical management skills. Our invited speakers will share insights into the research around the genetic basis of inherited cancer syndromes, including familial breast … Read more
Treatment-induced DNA methylation heterogeneity and implications for cell growth in Acute Myeloid Leukaemia This session will focus on hypomethylating agents (HMAs), which are used to treat people living with acute myeloid leukaemia (AML) and myelodysplasia. While these epigenetic therapies extend survival in many patients, low response rates and therapy-resistant relapse remain significant challenges. Relapse is … Read more
Enhancing HCC Surveillance: A Deep Dive into the Australian Clinical Practice GuidelinesIn this session discover the groundbreaking Clinical Practice Guidelines for Hepatocellular Carcinoma (HCC)surveillance in Australia. Developed alongside a diverse, multi-disciplinary team, these guidelines provide evidence-based recommendations to guide HCC surveillance for individuals at high risk. Don’t miss this opportunity to delve into the world … Read more
Educational Molecular Tumour BoardMelanoma Institute Australia – Personalised Immunotherapy ProgramPlease join us for this Educational Molecular Tumour Board Session with presenters from the Melanoma Institute Australia giving insight into their Personalised Immunotherapy Program. This presentation will cover:– The background around genomic, transcriptomic and tumour immune profiling as biomarkers of response to immunotherapies.– Biomarker multidisciplinary discussion … Read more
“Burning Issues in Radiotherapy Research”This session will provide a great opportunity to explore radiation oncology as a vibrant research sphere that researchers may never have considered before. Hear about the consumer experience, the role of biology in radiation research, the examination of technology and the role of radiation oncology clinical trials. SpeakersAssociate Professor Eric Hau. Radiation … Read more
“Preventing cardiovascular morbidity and mortality in cancer patients”Currently, there are over 30 million cancer survivors worldwide. Cancer survivorship is expected to grow by 30%, and it is estimated that about 2 million Australians by 2040 will be living beyond cancer. This is due to improvements in cancer screening, effective treatments and the aging of the … Read more
“The gut microbiome and neo-adjuvant immunotherapy: implications for efficacy and toxicity.”Immune checkpoint inhibitor (ICI) immunotherapies have revolutionised the treatment of melanoma, although drug resistance or concurrent immune-related adverse events (irAEs) still impact many patients. In this session the influence of the gut microbiome on clinical outcomes will be discussed using a large clinical trial cohort … Read more
Session InformationThe PREDICT program, funded by Cancer Council NSW, aims to develop a personalised chemotherapy dosing system for cancer patients to improve quality of life, reduce side effects and increase chance of survival. Current chemotherapy dosing is imprecise and not personalised. It is estimated that 20-30% of patients receiving chemotherapy will receive a dose that … Read more
Session InformationLymphodepletion chemotherapy followed by infusion of T cells that are genetically modified to express a chimeric antigen receptor (CAR) targeted to CD19 is a novel therapy for patients with relapsed and/or refractory B cell malignancies. In this seminar factors associated with outcomes of CAR-T cell therapy in adult B cell malignancies will be discussed … Read more
